1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsThis award supports research aimed at developing a safe and cross-protective vaccine that provides long-lasting immunity against Leptospira infection, irrespective of the infecting Leptospira serovar and affected host species.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Likely research institutions, universities, and other organizations capable of conducting biomedical research. Confirm the full requirements in the official notice before applying.
Developing Cross Protective Vaccine to Control Leptospira Infection (R21AI199507) is funded by National Institute of Allergy & Infectious Diseases (NIAID). Verify program details on the funder's official page before applying.
Past winners and funding trends for this program
Innovation Grant is a grant from the Blue Cross and Blue Shield of Louisiana Foundation that funds nonprofit organizations in Louisiana developing innovative, health-focused programs that improve the wellness and well-being of Louisianians. The foundation prioritizes creative approaches to addressing health disparities and improving access to health services for underserved populations. Eligible applicants are 501(c)(3) nonprofits based in Louisiana. Awards range from $10,000 to $100,000, with project eligibility and scope evaluated through a Letter of Intent (LOI) submission process. As of 2025, LOI submissions are completed through the lablue.smartsimple.com portal. The deadline for the most recent cycle was March 1, 2026.
Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA) promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports impactful, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with Duchenne muscular dystrophy (DMD) in the near term. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale. The DMDRP strongly encourages research projects investigating therapies designed to demonstrate efficacy cross the life span, including infants, toddlers and nonambulatory individuals.Distinctive Features: The FY26 DMDRP IDA mechanism offers three eligibility career categories:• The Established Investigator category is for independent investigators at all academic levels, or equivalent• The New Investigator – Early-Stage category is for independent investigators early in their careers (i.e., within 10 years of their first faculty appointment or equivalent). Applicants in this category will be reviewed separately from Established Investigators.• The New Investigator – Transitioning category is for independent investigators at all academic levels, or equivalent, in an area other than muscular dystrophy who are seeking to transition to a career in DMD, thereby bringing their expertise to the field. Applicants in this category will be reviewed separately from Established Investigators.Preliminary data relevant to DMD that supports the feasibility of the research hypotheses and research approaches are required for all applications. Clinical trials or clinical trial aims are not allowed. Funding Opportunity Number: HT942526DMDRPIDA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $2.5M total program funding.
The memorandum of agreement was signed August 4 and 5, disclosed by House appropriators on September 3, and runs through 2036. It names no dollar figure. Here is what is actually established, what is still speculation, and what researchers holding or planning NIAID biodefense awards should do before September 30.
Read articleThe ReVAMPP network funds vaccine and monoclonal antibody research across five virus families. Here is who won, what the prototype-pathogen strategy means, and how to position for the next round.
Read articlePAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read article